Lamattina John L's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Jun 12, 2026
- Accession no.
- 0002001011-26-000102
- Filed
- Jun 12, 2026
- Trade date
- Jun 10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $1.15M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lamattina John LCIK 0001216074 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Common Stock | SSaleDisposed | −257 | $247.22F1 | −$63,535.54 | 31,303 | Direct | |
| Jun 10, 2026 | Common Stock | SSaleDisposed | −232 | $248.11F2 | −$57,561.52 | 31,071 | Direct | |
| Jun 10, 2026 | Common Stock | SSaleDisposed | −697 | $249.53F3 | −$173,922.41 | 30,374 | Direct | |
| Jun 10, 2026 | Common Stock | SSaleDisposed | −3,405 | $251.62F4 | −$856,766.1 | 26,969 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.